Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | STK3 | Q13188 | 1/20 | 0.44 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 6/20 | 0.41 |
| ▸ | BRAF | P15056 | 6/20 | 0.41 |
| ▸ | KIF18A | Q8NI77 | 6/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL12806052 | 0.97 | CNR2 (0.47) | CNR2FGFR4GAAKDM4ECLK2 | |
| SCHEMBL1817976 | 0.94 | FGFR4 (0.47) | CNR2FGFR4GAAKDM4ECLK2 | |
| Trifluoroacetic Acid SCHEMBL12805716 | 0.91 | FGFR4 (0.45) | CNR2FGFR4GAAKDM4ECLK2 | |
| SCHEMBL18427269 | 0.91 | FGFR4 (0.44) | CNR2FGFR4GAAKDM4ECLK2 | |
| SCHEMBL1836710 | 0.88 | FGFR4 (0.46) | CNR2FGFR4GAAKDM4ECLK2 | |
| SCHEMBL18427329 | 0.88 | CNR2 (0.50) | CNR2GAAKDM4ECLK2GSK3A | |
| SCHEMBL12958958 | 0.86 | CNR2 (0.46) | CNR2FGFR4AR | |
| SCHEMBL12654443 | 0.85 | CNR2 (0.48) | CNR2GAAKDM4ECLK2GSK3A | |
| SCHEMBL12653771 | 0.85 | FGFR4 (0.54) | CNR2FGFR4 | |
| SCHEMBL12654380 | 0.84 | FGFR4 (0.52) | CNR2FGFR4CLK2GSK3BCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011059839-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR2 1081/4885FGFR4 1940/4885GAA 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.